Evommune, Inc. (EVMN) Financials

EVMN Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 322.5 million 17.9 million
Dec. 31, 2025 224.9 million 19.4 million
Sept. 30, 2025 84.5 million 267.7 million
June 30, 2025 96.2 million 267.4 million

EVMN Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -27.6 million 3.5 million
Dec. 31, 2025 -16.8 million 4.2 million
Sept. 30, 2025 -9.8 million 560000
June 30, 2025 -26.2 million ?

EVMN Net Income

No data available :(

EVMN Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 211.5 million - 7.3 million
Dec. 31, 2025 149.2 million - 1.5 million
Sept. 30, 2025 76.1 million 257.0 million 261000
June 30, 2025 86.8 million 257.0 million 347000

EVMN Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 33.7 million
Dec. 31, 2025 31.5 million
Sept. 30, 2025 31.5 million
June 30, 2025 30.1 million

EVMN Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 83000 17.3 million 6.3 million -
Dec. 31, 2025 104000 20.4 million 9.3 million -
Sept. 30, 2025 131000 19.6 million 3.7 million -
June 30, 2025 - 19.6 million 3.4 million -

EVMN Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 349000
Dec. 31, 2025 - 326000
Sept. 30, 2025 10.0 million 311000
June 30, 2025 - 375000

EVMN

Price: $20

52 week price:
13.89
33.20

Earnings Per Share: -2.11 USD

Exchange: NYQ

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 738.0 million

Links: